Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 5/20 | 0.46 |
| ▸ | BACE2 | Q9Y5Z0 | 4/20 | 0.46 |
| ▸ | REN | P00797 | 1/20 | 0.46 |
| ▸ | APP | P05067 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | LMNA | P02545 | 4/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | CTSD | P07339 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 2/20 | 0.38 |
| ▸ | HTR7 | P34969 | 2/20 | 0.38 |
| ▸ | HTR6 | P50406 | 2/20 | 0.38 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28127783 | 0.84 | BACE1 (0.38) | BACE1BACE2RENAPPTSHR | |
| SCHEMBL16865397 | 0.79 | BACE1 (0.43) | BACE1BACE2RENAPPTSHR | |
| SCHEMBL17794053 | 0.76 | LMNA (0.68) | BACE1BACE2RENAPPTSHR | |
| SCHEMBL16867619 | 0.76 | BACE1 (0.41) | BACE1BACE2RENAPPTSHR | |
| SCHEMBL17830174 | 0.75 | HTR1A (0.46) | BACE1BACE2RENAPPTSHR | |
| SCHEMBL16865414 | 0.75 | MAPT (0.53) | BACE1BACE2RENAPPTSHR | |
| SCHEMBL19923740 | 0.74 | HTR1A (0.46) | BACE1BACE2RENAPPTSHR | |
| SCHEMBL16865431 | 0.72 | CYP2C19 (0.41) | BACE1BACE2RENAPPTSHR | |
| SCHEMBL19923559 | 0.72 | HTR1A (0.42) | BACE1BACE2RENAPPTSHR | |
| SCHEMBL10645739 | 0.71 | ELANE (0.56) | BACE1TSHRCYP2C19ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11031630-B2 | Electrolyte and electrochemical device | NINGDE AMPEREX TECHNOLOGY LIMITED (CN) | 2021-06-08 | — | — | US | disclosed |
| US-20200243906-A1 | ELECTROLYTE AND ELECTROCHEMICAL DEVICE | NINGDE AMPEREX TECHNOLOGY LIMITED | 2020-07-30 | — | — | US | disclosed |
| EP-0137343-B1 | NOVEL OXOPYRIMIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Taro Pharmaceutical Industries Ltd. (IL) | 1991-12-04 | — | — | EP | disclosed |
| US-4628056-A | Novel oxopyrimidine derivatives, pharmaceutical compositions containing them and their use as anticonvulsant, antianxiety and muscle relaxant agents | TARO PHARMACEUTICAL INDUSTRIES LTD. (IL) | 1986-12-09 | — | — | US | disclosed |
| EP-0137343-A2 | Novel oxopyrimidine derivatives and pharmaceutical compositions containing them | Taro Pharmaceutical Industries Ltd. (IL) | 1985-04-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200243906-A1 | ELECTROLYTE AND ELECTROCHEMICAL DEVICE | CACNA1B, NCS1, CA3 | BACE1 4026/4885BACE2 4399/4885REN 2832/4885 |
| US-11031630-B2 | Electrolyte and electrochemical device | CACNA1B, NCS1, CA3 | BACE1 4026/4885BACE2 4399/4885REN 2832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.